Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
Status:
Completed
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
This is a single arm, phase I study to assess the tolerability of abatacept when combined
with cyclosporine and mycophenolate mofetil as graft versus host disease prophylaxis in
children undergoing unrelated hematopoietic stem cell transplant for serious non-malignant
diseases as well as to assess the immunological effects of abatacept. Participants will be
followed for 2 years.